Interpretation of the progress in esophageal cancer treatment in the 2024 American Society of Clinical Oncology Gastrointestinal Cancer Symposium
- VernacularTitle:2024年美国临床肿瘤学会胃肠肿瘤研讨会（ASCO-GI）食管癌治疗进展解读
- Author:
Xuxu ZHANG
1
;
Junhai LI
2
;
Xinyao XU
3
;
Jiahe LI
3
;
Jipeng ZHANG
3
;
Wei LI
3
;
Lei WANG
4
,
5
;
Qiang LU
3
Author Information
1. 1. Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi, P. R. China 2.Department of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi an, 710038, P. R. China
2. Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi, P. R. China
3. Department of Thoracic Surgery, The Second Affiliated Hospital, Air Force Medical University, Xi an, 710038, P. R. China
4. Department of Thoracic Surgery, Xincai People'
5. s Hospital of Henan Province, Xincai, 463500, Henan, P. R. China
- Publication Type:Journal Article
- Keywords:
Esophageal cancer;
ASCO Gastrointestinal Cancers Symposium;
clinical treatment;
interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2024;31(06):807-813
- CountryChina
- Language:Chinese
-
Abstract:
The 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) was held in San Francisco, the USA from January 18th to 20th, 2024 (local time). The multiple studies presented in this symposium will have a significant impact on the clinical practice of esophageal cancer. This article will focus on the surgical methods of esophageal cancer, perioperative immunotherapy, drug therapy for advanced esophageal cancer, rescue treatment after immunotherapy resistance, and other relevant aspects. It aims to summarize and interpret the significant advancements in the field of esophageal cancer presented in this symposium.
